NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Tavo Biotherapeutics

Tavo Biotherapeutics

Private
Laguna Beach, CaliforniaHealthcare & Life Scienceshttps://tavobio.com/

Last Round

Series A

Jun 2, 2026

Total Funding Raised

$29.2M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Tavo Biotherapeutics is a biopharmaceutical company developing novel therapeutics for ophthalmic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B2C

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

glaucoma treatmentophthalmology biotechdisease-modifying therapyclinical-stage biotechretinal disease treatmenttopical therapybispecific antibodyage-related macular degenerationAMDdiabetic retinopathyautonomic nervous system modulatorVEGF inhibitorneuroprotection

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Tavo Biotherapeutics Comparables

Compare Tavo Biotherapeutics with similar companies based on industry and business-model similarity.

Tavo Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Tavo Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 2, 2026
GrantSep 1, 2024

Key People

Founding team and executive leadership

Monica M. Jablonski

Founder And Chief Scientific Officer

Founding Team

Gary Berman

CEO

Executive Team

Tavo Biotherapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 2, 2026

    $17M round led by Pureos Bioventures.

  • Apr 2, 2026

    Monthly visitors increased 74% MoM, reaching 3K.

Tavo Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Tavo Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Tavo Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLaguna Beach, California
Employee Range15
Year Founded2024
Last FundingJun 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.